Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 1 of 1 (100%) have an AI response strategy ready
Glycomimetics Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, CHO, DAVID H. The prosecution is occurring within 1 distinct art unit, which indicates a specialized technical focus for the company's active pharmaceutical filings. This concentration within a single art unit suggests that the biotechnology claims are being evaluated against a specific set of technical standards.
The busiest examiner, CHO, DAVID H, is managing 1 pending office action. Because there is only 1 distinct examiner involved in the 1 pending action, the company's current prosecution is highly centralized. Practitioners can focus their strategy on the specific feedback provided by this single examiner. The busiest examiner pending figure of 1 confirms that there is no distribution of the workload across other officials, making the examiner's individual feedback the primary factor in the current prosecution phase.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHO, DAVID H | 1 | 31.9% | +67.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998942 | COMPOUNDS AND METHODS FOR REDUCTION OF CANCER CELL BURDEN AND PROTECTION OF NORMAL HEMATOPOIESIS | CHO, DAVID H | 4d overdue |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17998942 | COMPOUNDS AND METHODS FOR REDUCTION OF CANCER CELL BURDEN AND PROTECTION OF NORMAL HEMATOPOIESIS | CHO, DAVID H | 1693 | §103Other | Non-Final OA | 4d overdue | AI Ready | Nov 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial